Literature DB >> 15183143

Interferon alpha--a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity.

D Devendra1, G S Eisenbarth.   

Abstract

The incidence of type 1 diabetes has been rapidly rising. Environmental factors such as viruses have been implicated as a possible agent accounting for this rise. Enteroviruses have recently been the focus in many research studies as a potential agent in the pathogenesis of type 1 diabetes. The mechanism of viral infection leading to beta cell destruction not only involves multiple pathways but also the cytokine-interferon alpha (IFN-alpha). Our hypothesis is that activation of toll receptors by double-stranded RNA or poly-IC (viral mimic) through induction of IFN-alpha may activate or accelerate immune-mediated beta cell destruction. Numerous clinical case reports have implicated that IFN-alpha therapy is associated with autoimmune diseases and that elevated serum IFN-alpha levels have been associated with type 1 diabetes. In multiple animal models, given specific genetic susceptibility, poly-IC can induce insulitis or diabetes. Therapeutic agents targeting IFN-alpha may potentially be beneficial in the prevention of type 1 diabetes and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183143     DOI: 10.1016/j.clim.2004.01.008

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  33 in total

Review 1.  Type 1 diabetes: recent developments.

Authors:  Devasenan Devendra; Edwin Liu; George S Eisenbarth
Journal:  BMJ       Date:  2004-03-27

Review 2.  Genetic regulation of serum cytokines in systemic lupus erythematosus.

Authors:  Silvia N Kariuki; Timothy B Niewold
Journal:  Transl Res       Date:  2009-09-25       Impact factor: 7.012

3.  TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts.

Authors:  Thomas B Thornley; Michael A Brehm; Thomas G Markees; Leonard D Shultz; John P Mordes; Raymond M Welsh; Aldo A Rossini; Dale L Greiner
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

Review 4.  Should we inhibit type I interferons in sepsis?

Authors:  Tina Mahieu; Claude Libert
Journal:  Infect Immun       Date:  2006-09-25       Impact factor: 3.441

5.  Activation of innate immunity accelerates sialoadenitis in a mouse model for Sjögren's syndrome-like disease.

Authors:  S-R Nandula; Y M Scindia; P Dey; H Bagavant; U S Deshmukh
Journal:  Oral Dis       Date:  2011-08-04       Impact factor: 3.511

Review 6.  Interferon alpha: The key trigger of type 1 diabetes.

Authors:  Angela Lombardi; Effie Tsomos; Sara S Hammerstad; Yaron Tomer
Journal:  J Autoimmun       Date:  2018-08-14       Impact factor: 7.094

7.  Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity.

Authors:  Mihaela Stefan; Chengguo Wei; Angela Lombardi; Cheuk Wun Li; Erlinda S Concepcion; William B Inabnet; Randall Owen; Weijia Zhang; Yaron Tomer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-13       Impact factor: 11.205

Review 8.  Triggers and drivers of autoimmunity: lessons from coeliac disease.

Authors:  Ludvig M Sollid; Bana Jabri
Journal:  Nat Rev Immunol       Date:  2013-03-15       Impact factor: 53.106

9.  Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C.

Authors:  Aspasia S Soultati; Spyridon P Dourakis; Alexandra Alexopoulou; Melanie Deutsch; Athanasios J Archimandritis
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

10.  Interferons and their potential in the treatment of ocular inflammation.

Authors:  Friederike Mackensen; Regina Max; Matthias D Becker
Journal:  Clin Ophthalmol       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.